Compare Cassava Sciences Inc (FLNA) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs LyondellBasell Industries NV — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while LyondellBasell Industries NV trades at $60.32 (market cap $19.49B). The key difference: LyondellBasell Industries NV is far larger — about 494.7× Cassava Sciences Inc's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and LyondellBasell Industries NV for 87 Days on average.
| FLNA | LYB | |
|---|---|---|
Market Cap | $39.40M | $19.49B |
Volume | 759,018 | 6,033,396 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $82.38 |
52-Week Low | $0.68 | $42.28 |
Typical Hold Time | 37 Days | 87 Days |
Enterprise Value | -$43.28M | $31.08B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
LYB trades at $60.90, up 4.12% today, with a bearish technical signal and mixed fundamentals. Revenue declined to $30.15B in 2025, with a net loss of $745M, though recent quarters show earnings beats. The stock is near its 52-week low, with key support at $60. Analyst consensus is split evenly between Buy and Hold, with a $69.38 price target. Recent news highlights dividend sustainability concerns amid chemical sector volatility.
Outlook remains cautious due to profitability challenges and high debt, but operational improvements and a 45% analyst buy rating suggest recovery potential. Risks include cyclical demand, margin pressure, and dividend coverage issues. The stock offers value at current levels if earnings stabilize, but investors should monitor cash flow trends and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
